Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: 50 mg/mL Virazole Inhalant Product; Drug: 100 mg/mL Virazole Inhalant Product; Drug: Placebo

• Registration Number: NCT05229510
• Lead Sponsor: Bausch Health Americas, Inc.

Brief Summary

This study is a Phase 1a, randomized, double-blind, placebo-controlled, safety, tolerability, and PK study in healthy adult volunteers.

Participants were screened for eligibility within 14 days prior to enrollment. Four successive cohorts were enrolled, with each cohort receiving a single dose of Virazole or placebo using different delivery regimens.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-12
• Primary Completion: 2021-07-12
• Study Completion: 2021-07-12
• Status Verified: 2022-01
• Study First Submitted: 2022-01-28
• Study First Submitted QC: 2022-01-28
• Last Update Submitted: 2022-01-28
• Study First Posted: 2022-02-08
• Last Update Posted: 2022-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

1. Subject is a male or female ≥ 18 and ≤65 years of age.

2. For a female, must be of non-childbearing potential according to 1 of the following criteria at least 6 months prior to screening:

   • hysteroscopic sterilization;
   • bilateral tubal ligation or bilateral salpingectomy;
   • post-menopausal with spontaneous amenorrhea for ≥ 12 consecutive months with follicle-stimulating hormone [FSH] > 25.8 mIU/mL; or
   • having had bilateral oophorectomy (with or without hysterectomy).

3. For a male subject must be vasectomized with confirmed postvasectomy semen analysis or a male subject with a documented diagnostic of infertility.

4. Subject willing and able to provide written informed consent.

5. Subject has a body mass index (BMI) ≥ 18.50 and < 30.00 kg/m2.

6. Subject is in good general health without clinically significant haematological, cardiac, respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or malignant disease, as determined by the Investigator.

7. Subject has suitable venous access for blood sampling

Exclusion Criteria

1. Subject has a history of hypersensitivity to ribavirin.
2. Subject has a history of asthma, COPD, or bronchospasm.
3. Subject has anemia defined as hemoglobin or RBC <75% of the institutional lower limit of normal for age and gender.
4. Subject has any major illness or systemic infection (including COVID-19) within 4 weeks of the Screening Visit or has a clinically relevant history or is currently suffering from a disease or condition that, in the opinion of the Investigator, may affect the evaluation of the study drug or place the subjects at undue risk.
5. Subject is seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), or positive for SARS-CoV-2 at Screening.
6. Subject has a clinically relevant history of or current evidence of abuse of alcohol or other drug(s).
7. Subject is currently a tobacco smoker or was a tobacco smoker within 6 months of the Baseline Visit.
8. Subject has donated 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, Clinical Studies, etc.) in the previous 56 days prior to the Baseline Visit.
9. Subject is currently participating in any drug or device clinical investigation or has received an investigational agent or approved drug that, in the Investigator's judgement, may have a chemical or pharmacological interaction with Virazole if administered within 5 half-lives or 30 days of the Baseline Visit.
10. Subject has any condition that could cause noncompliance with treatment or may otherwise contraindicate the subject's participation in the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
50 mg/mL Virazole (10 ml total volume)	50 mg/mL Virazole Inhalant Product	50 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
50 mg/mL Virazole (20 ml total volume)	50 mg/mL Virazole Inhalant Product	50 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
100 mg/mL Virazole (10 ml total volume)	100 mg/mL Virazole Inhalant Product	100 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
100 mg/mL Virazole (20 ml total volume)	100 mg/mL Virazole Inhalant Product	100 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
Placebo	Placebo	Placebo aerosolized and administered until solution depleted

Primary Outcome Measures

Name	Time	Method
Percentage of participants with treatment-emergent adverse events (TEAEs)	40 days

Trial Locations

Locations (1)

Bausch Site 1; 🇨🇦 Mississauga, Ontario, Canada